SCHEMBL9176367

SCHEMBL9176367

N#Cc1ccc(N2CCC(CO)CC2)cc1

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.53
TP53 P04637 1/20 0.53
CHRNA10 Q9GZZ6 1/20 0.49
CHRNA9 Q9UGM1 1/20 0.49
CHRM4 P08173 2/20 0.46
DPP4 P27487 1/20 0.46
CTSS P25774 1/20 0.43
CTSK P43235 1/20 0.43
SIGMAR1 Q99720 2/20 0.43
HRH3 Q9Y5N1 2/20 0.43
POLB P06746 1/20 0.43
KMT2A Q03164 1/20 0.42
PDE4D Q08499 1/20 0.42
NOTUM Q6P988 1/20 0.42
USP14 P54578 1/20 0.41
PARP1 P09874 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9170130 0.83 KDM4E (0.53) KDM4ETP53CHRNA10CHRNA9CHRM4
SCHEMBL10243310 0.83 CHRNA10 (0.56) KDM4ETP53CHRNA10CHRNA9CHRM4
SCHEMBL31753332 0.83 HRH3 (0.48) KDM4ETP53CHRNA10CHRNA9CHRM4
SCHEMBL7528095 0.81 MEN1 (0.47) KDM4ETP53CHRNA10CHRNA9CTSS
SCHEMBL21136632 0.81 MEN1 (0.47) KDM4ETP53CHRNA10CHRNA9CTSS
SCHEMBL21135569 0.81 MEN1 (0.47) KDM4ETP53CHRNA10CHRNA9CTSS
SCHEMBL7753402 0.81 FFAR4 (0.52) KDM4ETP53CHRNA10CHRNA9CHRM4
SCHEMBL2455962 0.81 KDM4E (0.58) KDM4ETP53CHRNA10CHRNA9DPP4
SCHEMBL18588518 0.81 KDM4E (0.50) KDM4ETP53CHRNA10CHRNA9CHRM4
SCHEMBL11232968 0.80 KDM4E (0.49) KDM4ETP53CHRNA10CHRNA9CHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3371196-B1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PLATELET AGGREGATION UNIV MONTREAL (CA) 2021-10-27 EP disclosed
US-10329307-B2 Heterocyclic compounds as inhibitors of platelet aggregation UNIVERSITE DE MONTREAL (CA) 2019-06-25 US disclosed
US-5442064-A Anticoagulants, antiagglomerants DR. KARL THOMAE GMBH (DE) 1995-08-15 US disclosed
CN-1087904-A Carboxylic acid derivative, the pharmaceutical composition that contains these compounds with and preparation method thereof KRAL THOMAE GMBH (DE) 1994-06-15 CN disclosed
EP-0592949-A2 N-(aminocarbonyl)-piperidines/pepirazines as aggregation inhibiting agents Dr. Karl Thomae GmbH (DE) 1994-04-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10329307-B2 Heterocyclic compounds as inhibitors of platelet aggregation F12, F2, F3 KDM4E 2886/4885TP53 3139/4885CHRNA10 2581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.